Stage 1 HypertensionPhase 3NCT01508026
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
A Phase 3 study testing Nebivolol and Valsartan 1, Nebivolol and Valsartan 2 and Nebivolol and Valsartan 3 in people with Stage 1 Hypertension and Stage 2 Hypertension, run by Forest Laboratories at 413 sites in United States.
Trial summary
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stage 1 Hypertension, Stage 2 Hypertension
- What is being tested?
- Nebivolol and Valsartan 1, Nebivolol and Valsartan 2 and Nebivolol and Valsartan 3
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 4,161 participants
- Where
- 413 sitesUnited States
- Study dates
- Jan 2012to May 2013
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female outpatients of age 18 years or above
- Patients diagnosed with stage 1 or stage 2 essential hypertension
- Normal physical examination findings, electrocardiogram (ECG) results and chest x-ray; or abnormal findings judged by the Investigator to be not clinically significant
Who cannot join
- Secondary hypertension or severe hypertension
- Clinically significant cardiovascular disease or heart failure
- Clinical significant respiratory disease that would prohibit the use of a beta blocker
- A medical contraindication to discontinuing a current antihypertensive therapy
- History of Type 1 diabetes mellitus
- History of Severe Mental Illness except mild depression
Trial locations and contacts
413 sites in 1 country.
300 sites in 1 country
United States300 sites
Forest Investigative Site 1790
Addison, Illinois, 60101
Forest Investigative Site 1203
Akron, Ohio, 44311
Forest Investigative Site 1761
Albuquerque, New Mexico, 87102
Forest Investigative Site 1094
Arlington, Texas, 76012
Forest Investigative Site 1786
Arlington, Virginia, 22203
Forest Investigative Site 1130
Arlington, Virginia, 22205
Forest Investigative Site 1093
Arlington Heights, Illinois, 60004
Forest Investigative Site 1040
Asheboro, North Carolina, 27203
Forest Investigative Site 1116
Ashland, Oregon, 97520
Forest Investigative Site 1281
Atlanta, Georgia, 30308
Forest Investigative Site 1745
Atlanta, Georgia, 30338
Forest Investigative Site 1769
Auburn, Maine, 04210
Forest Investigative Site 1107
Augusta, Kansas, 67010
Forest Investigative Site 1245
Austin, Texas, 78728
Forest Investigative Site 1311
Austin, Texas, 78756
Forest Investigative Site 1125
Baltimore, Maryland, 21209
Forest Investigative Site 1263
Baltimore, Maryland, 21236
Forest Investigative Site 1251
Baton Rouge, Louisiana, 70808
Forest Investigative Site 1174
Beaumont, Texas, 77701
Forest Investigative Site 1028
Bellevue, Nebraska, 68005
Forest Investigative Site 1025
Belzoni, Mississippi, 39038
Forest Investigative Site 1109
Bensalem, Pennsylvania, 19020
Forest Investigative Site 1291
Bensalem, Pennsylvania, 19020
Forest Investigative Site 1750
Birmingham, Alabama, 35216
Forest Investigative Site 1038
Birmingham, Alabama, 35235
Forest Investigative Site 1308
Birmingham, Alabama, 35235
Forest Investigative Site 1192
Birmingham, Alabama, 35242
Forest Investigative Site 1005
Birmingham, Alabama, 35294
Forest Investigative Site 1398
Blackfoot, Idaho, 83221
Forest Investigative Site 1080
Blue Ridge, Georgia, 30513
Forest Investigative Site 1159
Boca Raton, Florida, 33432
Forest Investigative Site 1762
Boerne, Texas, 78006
Forest Investigative Site 1727
Boise, Idaho, 83704
Forest Investigative Site 1007
Bradenton, Florida, 34208
Forest Investigative Site 1042
Brandon, Florida, 33511
Forest Investigative Site 1324
Bridgeport, Connecticut, 06610
Forest Investigative Site 1402
Bristol, Tennessee, 37620
Forest Investigative Site 1796
Brooklyn, New York, 11203
Forest Investigative Site 1702
Brooksville, Florida, 34601
Forest Investigative Site 1090
Broomall, Pennsylvania, 19008
Forest Investigative Site 1244
Bryan, Texas, 77802
Forest Investigative Site 1063
Buena Park, California, 90620
Forest Investigative Site 1151
Buffalo, New York, 14215
Forest Investigative Site 1743
Burbank, California, 91505
Forest Investigative Site 1020
Burke, Virginia, 22015
Forest Investigative Site 1073
Burlington, North Carolina, 27215
Forest Investigative Site 1210
Canal Fulton, Ohio, 44614
Forest Investigative Site 1006
Carmichael, California, 95608
Forest Investigative Site 1218
Carnegie, Pennsylvania, 15106
Forest Investigative Site 1776
Carrollton, Texas, 75006
Forest Investigative Site 1142
Cary, North Carolina, 27519
Forest Investigative Site 1760
Charleston, South Carolina, 29407
Forest Investigative Site 1363
Charleston, South Carolina, 29412
Forest Investigative Site 1377
Charleston, West Virginia, 25304
Forest Investigative Site 1733
Charlotte, North Carolina, 28209
Forest Investigative Site 1067
Charlotte, North Carolina, 28277
Forest Investigative Site 1037
Chattanooga, Tennessee, 37421
Forest Investigative Site 1336
Chelsea, Michigan, 48118
Forest Investigative Site 1747
Chicago, Illinois, 60607
Forest Investigative Site 1071
Chicago, Illinois, 60611
Forest Investigative Site 1752
Chicago, Illinois, 60616
Forest Investigative Site 1384
Chino, California, 91710
Forest Investigative Site 1190
Chula Vista, California, 91911
Forest Investigative Site 1012
Cincinnati, Ohio, 45219
Forest Investigative Site 1721
Cincinnati, Ohio, 45219
Forest Investigative Site 1280
Cincinnati, Ohio, 45224
Forest Investigative Site 1798
Cincinnati, Ohio, 45227
Forest Investigative Site 1732
Cincinnati, Ohio, 45236
Forest Investigative Site 1718
Cincinnati, Ohio, 45242
Forest Investigative Site 1062
Cincinnati, Ohio, 45246
Forest Investigative Site 1050
Cincinnati, Ohio, 45249
Forest Investigative Site 1031
Clarksville, Tennessee, 37043
Forest Investigative Site 1764
Clearwater, Florida, 33756
Forest Investigative Site 1084
Cleveland, Ohio, 44122
Forest Investigative Site 1015
Clinton, Utah, 84015
Forest Investigative Site 1074
Collierville, Tennessee, 38107
Forest Investigative Site 1162
Colorado Springs, Colorado, 80904
Forest Investigative Site 1122
Columbia, South Carolina, 29204
Forest Investigative Site 1765
Columbus, Ohio, 43213
Forest Investigative Site 1395
Columbus, Ohio, 43214
Forest Investigative Site 1182
Coral Gables, Florida, 33134
Forest Investigative Site 1249
Coral Gables, Florida, 33134
Forest Investigative Site 1205
Corpus Christi, Texas, 78404
Forest Investigative Site 1268
Corsicana, Texas, 75110
Forest Investigative Site 1178
Costa Mesa, California, 92626
Forest Investigative Site 1215
Covington, Louisiana, 70433
Forest Investigative Site 1801
Crestview Hills, Kentucky, 41017
Forest Investigative Site 1045
Cromwell, Connecticut, 06416
Forest Investigative Site 1221
Cutler Bay, Florida, 33189
Forest Investigative Site 1185
Dakota Dunes, South Dakota, 57049
Forest Investigative Site 1213
Dallas, Texas, 75235
Forest Investigative Site 1343
Danville, Virginia, 24541
Forest Investigative Site 1793
Daytona Beach, Florida, 32117
Forest Investigative Site 1266
Deerfield Beach, Florida, 33441
Forest Investigative Site 1100
DeFuniak Springs, Florida, 32435
Forest Investigative Site 1734
DeLand, Florida, 32720
Forest Investigative Site 1209
Delaware, Ohio, 43015
Forest Investigative Site 1270
Denver, Colorado, 80209
Forest Investigative Site 1711
Denver, Colorado, 80220
Forest Investigative Site 1043
Diamond Bar, California, 91765
Forest Investigative Site 1775
Doral, Florida, 33166
Forest Investigative Site 1378
Doral, Florida, 33172
Forest Investigative Site 1163
Downington, Pennsylvania, 19335
Forest Investigative Site 1187
Draper, Utah, 84020
Forest Investigative Site 1226
Draper, Utah, 84020
Forest Investigative Site 1342
Dunn, North Carolina, 28334
Forest Investigative Site 1237
Edgewater, Florida, 32132
Forest Investigative Site 1709
Edison, New Jersey, 08817
Forest Investigative Site 1362
Encinitas, California, 92024
Forest Investigative Site 1118
Erie, Pennsylvania, 16508
Forest Investigative Site 1171
Erie, Pennsylvania, 16509
Forest Investigative Site 1379
Eugene, Oregon, 97402
Forest Investigative Site 1780
Eugene, Oregon, 97404
Forest Investigative Site 1274
Eunice, Louisiana, 70535
Forest Investigative Site 1091
Evansville, Indiana, 47710
Forest Investigative Site 1103
Evansville, Indiana, 47712
Forest Investigative Site 1033
Fayetteville, Tennessee, 37334
Forest Investigative Site 1097
Flint, Michigan, 48504
Forest Investigative Site 1047
Foley, Alabama, 36535
Forest Investigative Site 1068
Fort Lauderdale, Florida, 33306
Forest Investigative Site 1026
Fort Lauderdale, Florida, 33308
Forest Investigative Site 1330
Fort Lauderdale, Florida, 33319
Forest Investigative Site 1388
Fremont, Nebraska, 68025-2300
Forest Investigative Site 1313
Fremont, Nebraska, 68025
Forest Investigative Site 1144
Fresno, California, 93721
Forest Investigative Site 1095
Fresno, California, 93726
Forest Investigative Site 1794
Gainsville, Florida, 32605
Forest Investigative Site 1710
Garden Grove, California, 92844
Forest Investigative Site 1021
Glen Falls, New York, 12801
Forest Investigative Site 1145
Glendale, Arizona, 85308
Forest Investigative Site 1703
Goodyear, Arizona, 85395
Forest Investigative Site 1022
Greenbrae, California, 94904
Forest Investigative Site 1088
Greensboro, North Carolina, 27401
Forest Investigative Site 1385
Greensboro, North Carolina, 27408
Forest Investigative Site 1309
Greensboro, North Carolina, 27410
Forest Investigative Site 1133
Greenville, South Carolina, 29615
Forest Investigative Site 1809
Greenville, South Carolina, 29615
Forest Investigative Site 1327
Greer, South Carolina, 29651
Forest Investigative Site 1717
Gulf Shores, Alabama, 36542
Forest Investigative Site 1132
Haddon Heights, New Jersey, 08035
Forest Investigative Site 1261
Hallandale, Florida, 33009
Forest Investigative Site 1726
Haverhill, Massachusetts, 01830
Forest Investigative Site 1387
Hayden Lake, Idaho, 83835
Forest Investigative Site 1403
Hazel Crest, Illinois, 60429
Forest Investigative Site 1044
Henderson, Nevada, 89014
Forest Investigative Site 1052
Henderson, Nevada, 89052
Forest Investigative Site 1240
Hialeah, Florida, 33012
Forest Investigative Site 1260
Hialeah, Florida, 33012
Forest Investigative Site 1306
Hickory, North Carolina, 28601
Forest Investigative Site 1098
Hickory, North Carolina, 28602
Forest Investigative Site 1108
Hillsboro, Oregon, 97123-4147
Forest Investigative Site 1383
Holland, Pennsylvania, 18966
Forest Investigative Site 1155
Hollywood, Florida, 33021
Forest Investigative Site 1018
Honolulu, Hawaii, 96814
Forest Investigative Site 1228
Houston, Texas, 77024
Forest Investigative Site 1372
Houston, Texas, 77024
Forest Investigative Site 1777
Houston, Texas, 77030
Forest Investigative Site 1157
Houston, Texas, 77036
Forest Investigative Site 1360
Houston, Texas, 77062
Forest Investigative Site 1230
Houston, Texas, 77074
Forest Investigative Site 1774
Houston, Texas, 77081
Forest Investigative Site 1370
Huntington Beach, California, 92647
Forest Investigative Site 1704
Huntington Park, California, 90255
Forest Investigative Site 1725
Huntington Park, California, 90255
Forest Investigative Site 1345
Hutchinson, Kansas, 67502
Forest Investigative Site 1061
Hyannis, Massachusetts, 02601
Forest Investigative Site 1262
Irving, Texas, 75039
Forest Investigative Site 1057
Jackson, Mississippi, 39289-1214
Forest Investigative Site 1233
Jacksonville, Florida, 32216
Forest Investigative Site 1253
Jacksonville, Florida, 32216
Forest Investigative Site 1264
Jacksonville, Florida, 32216
Forest Investigative Site 1256
Jacksonville, Florida, 32223
Forest Investigative Site 1720
Jenkintown, Pennsylvania, 19046
Forest Investigative Site 1077
Jupiter, Florida, 33458
Forest Investigative Site 1165
Kalamazoo, Michigan, 49009
Forest Investigative Site 1782
Kansas City, Missouri, 64111
Forest Investigative Site 1763
Kingsport, Tennessee, 37660
Forest Investigative Site 1041
Kissimmee, Florida, 34741
Forest Investigative Site 1399
Kissimmee, Florida, 34741
Forest Investigative Site 1744
Knoxville, Tennessee, 37920
Forest Investigative Site 1742
La Mesa, California, 91942
Forest Investigative Site 1207
Lansdale, Pennsylvania, 19446
Forest Investigative Site 1011
Las Vegas, Nevada, 89101
Forest Investigative Site 1376
Las Vegas, Nevada, 89103
Forest Investigative Site 1019
Las Vegas, Nevada, 89104
Forest Investigative Site 1807
Las Vegas, Nevada, 89123
Forest Investigative Site 1048
Las Vegas, Nevada, 89148
Forest Investigative Site 1805
Lenexa, Kansas, 66219
Forest Investigative Site 1110
Lenoir, North Carolina, 28645
Forest Investigative Site 1366
Lexington, Kentucky, 40509
Forest Investigative Site 1236
Lilburn, Georgia, 30047
Forest Investigative Site 1141
Linden, New Jersey, 07036
Forest Investigative Site 1290
Little Rock, Arkansas, 72204
Forest Investigative Site 1138
Little Rock, Arkansas, 72211
Forest Investigative Site 1381
Lomita, California, 90717
Forest Investigative Site 1706
Long Beach, California, 90806
Forest Investigative Site 1229
Longview, Texas, 75605
Forest Investigative Site 1248
Los Angelas, California, 90057
Forest Investigative Site 1785
Los Angelas, California, 90057
Forest Investigative Site 1029
Los Angeles, California, 90017
Forest Investigative Site 1361
Los Angeles, California, 90017
Forest Investigative Site 1102
Los Angeles, California, 90036
Forest Investigative Site 1770
Louisville, Kentucky, 40213
Forest Investigative Site 1128
Lutherville, Maryland, 21093
Forest Investigative Site 1201
Lyndhurst, Ohio, 44124
Forest Investigative Site 1177
Madisonville, Kentucky, 42431
Forest Investigative Site 1086
Magna, Utah, 84044
Forest Investigative Site 1164
Manassas, Virginia, 20110
Forest Investigative Site 1389
Marietta, Georgia, 30060
Forest Investigative Site 1002
Marietta, Georgia, 30066
Forest Investigative Site 1246
Maumee, Ohio, 43537
Forest Investigative Site 1358
Memphis, Tennessee, 38119
Forest Investigative Site 1082
Memphis, Tennessee, 38125
Forest Investigative Site 1004
Meridian, Idaho, 83646
Forest Investigative Site 1757
Mesa, Arizona, 85202
Forest Investigative Site 1323
Metairie, Louisiana, 70006
Forest Investigative Site 1795
Metairie, Louisiana, 77002
Forest Investigative Site 1784
Miami, Florida, 33014
Forest Investigative Site 1364
Miami, Florida, 33125
Forest Investigative Site 1206
Miami, Florida, 33135
Forest Investigative Site 1397
Miami, Florida, 33136
Forest Investigative Site 1180
Miami, Florida, 33143
Forest Investigative Site 1396
Miami, Florida, 33144
Forest Investigative Site 1154
Miami, Florida, 33155
Forest Investigative Site 1788
Miami, Florida, 33169
Forest Investigative Site 1223
Miami, Florida, 33183
Forest Investigative Site 1707
Miami, Florida, 33185
Forest Investigative Site 1282
Miami, Florida, 33186
Forest Investigative Site 1297
Miami Springs, Florida, 33166
Forest Investigative Site 1367
Milwaukee, Wisconsin, 53215
Forest Investigative Site 1255
Mission, Kansas, 66202
Forest Investigative Site 1054
Mission Hills, California, 91345
Forest Investigative Site 1326
Missoula, Montana, 59808
Forest Investigative Site 1056
Mobile, Alabama, 36617
Forest Investigative Site 1272
Mooresville, North Carolina, 28117
Forest Investigative Site 1386
Moreno Valley, California, 92553
Forest Investigative Site 1126
Morton, Illinois, 61550
Forest Investigative Site 1135
Mount Gilead, Ohio, 43338
Forest Investigative Site 1127
Mt. Pleasant, South Carolina, 29464
Forest Investigative Site 1147
Muncie, Indiana, 47304
Forest Investigative Site 1310
Murrells Inlet, South Carolina, 29576
Forest Investigative Site 1719
Muscle Shoals, Alabama, 35662
Forest Investigative Site 1039
Nampa, Idaho, 83686
Forest Investigative Site 1199
New Braunfels, Texas, 78130
Forest Investigative Site 1285
New Orleans, Louisiana, 70115
Forest Investigative Site 1779
New Orleans, Louisiana, 70119
Forest Investigative Site 1708
New Port Richey, Florida, 34652
Forest Investigative Site 1756
Newport Beach, California, 92663
Forest Investigative Site 1092
Newton, Kansas, 67114
Forest Investigative Site 1767
Norfolk, Virginia, 23510
Forest Investigative Site 1195
Norman, Oklahoma, 73069
Forest Investigative Site 1314
Norristown, Pennsylvania, 19401
Forest Investigative Site 1728
North Dartmouth, Massachusetts, 02747
Forest Investigative Site 1176
North Miami Beach, Florida, 33162
Forest Investigative Site 1013
Northglenn, Colorado, 80234
Forest Investigative Site 1181
Northridge, California, 91325
Forest Investigative Site 1283
O'Fallon, Illinois, 62269
Forest Investigative Site 1390
Oakwood, Georgia, 30566
Forest Investigative Site 1216
Ogden, Utah, 84405
Forest Investigative Site 1184
Oklahoma City, Oklahoma, 73103
Forest Investigative Site 1305
Oklahoma City, Oklahoma, 73103
Forest Investigative Site 1759
Oklahoma City, Oklahoma, 73103
Forest Investigative Site 1284
Oldsmar, Florida, 34677
Forest Investigative Site 1034
Olive Branch, Mississippi, 38654
Forest Investigative Site 1035
Omaha, Nebraska, 68114
Forest Investigative Site 1016
Omaha, Nebraska, 68134
Forest Investigative Site 1254
Omaha, Nebraska, 68134
Forest Investigative Site 1148
Omaha, Nebraska, 68144
Forest Investigative Site 1232
Opa-locka, Florida, 33054
Forest Investigative Site 1212
Orange, California, 92868
Forest Investigative Site 1219
Orem, Utah, 84058
Forest Investigative Site 1802
Orlando, Florida, 32806
Forest Investigative Site 1049
Orlando, Florida, 32811
Forest Investigative Site 1235
Orlando, Florida, 32822
Forest Investigative Site 1741
Ormond Beach, Florida, 32174
Forest Investigative Site 1003
Oviedo, Florida, 32765
Forest Investigative Site 1369
Palm Harbor, Florida, 34684
Forest Investigative Site 1101
Palm Springs, California, 92262
Forest Investigative Site 1014
Paramount, California, 90723
Forest Investigative Site 1227
Paramus, New Jersey, 07652
Forest Investigative Site 1152
Pelzer, South Carolina, 29669
Forest Investigative Site 1079
Pembroke Pines, Florida, 33024
Forest Investigative Site 1053
Pembroke Pines, Florida, 33026
Forest Investigative Site 1055
Pembroke Pines, Florida, 33028
Forest Investigative Site 1161
Pembroke Pines, Florida, 33028
Forest Investigative Site 1166
Pembroke Pines, Florida, 33028
Forest Investigative Site 1224
Pembroke Pines, Florida, 33028
Forest Investigative Site 1075
Pembroke Pines, Florida, 33029
Forest Investigative Site 1198
Penndel, Pennsylvania, 19047
Forest Investigative Site 1322
Perrysburg, Ohio, 43551
Forest Investigative Site 1292
Petersburg, Virginia, 23803
Forest Investigative Site 1293
Philadelphia, Pennsylvania, 19152
Forest Investigative Site 1170
Phoenix, Arizona, 85015
Forest Investigative Site 1238
Phoenix, Arizona, 85018
Forest Investigative Site 1204
Phoenix, Arizona, 85020
Forest Investigative Site 1755
Phoenix, Arizona, 85020
Forest Investigative Site 1259
Phoenix, Arizona, 85032
Forest Investigative Site 1001
Phoenix, Arizona, 85050
Forest Investigative Site 1271
Picayune, Mississippi, 39466
Forest Investigative Site 1371
Pine Bluff, Arkansas, 71603
About this study
Official title: A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
- Conditions
- Stage 1 Hypertension, Stage 2 Hypertension
- Being tested
- Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2
- Keywords
- Stage 1, Stage 2, Hypertension
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nebivolol and Valsartan 1Drug
Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
Nebivolol and Valsartan 2Drug
Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
Nebivolol and Valsartan 3Drug
Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
Nebivolol 1Drug
Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
Nebivolol 2Drug
Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
Valsartan 1Drug
Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
Valsartan 2Drug
Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
PlaceboDrug
Dose matched placebo, oral administration
| Study group | Role | What they receive |
|---|---|---|
| Nebivolol and Valsartan Fixed Dose Combination 1 | Experimental | Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg Receives: Drug: Nebivolol and Valsartan 1 |
| Nebivolol and Valsartan Fixed Dose Combination 2 | Experimental | Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg Receives: Drug: Nebivolol and Valsartan 2 |
| Nebivolol and Valsartan Fixed Dose Combination 3 | Experimental | Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg Receives: Drug: Nebivolol and Valsartan 3 |
| Nebivolol Low Dose | Experimental | Nebivolol Monotherapy 5 mg Receives: Drug: Nebivolol 1 |
| Nebivolol High Dose | Experimental | Nebivolol Monotherapy 20 mg Receives: Drug: Nebivolol 2 |
| Valsartan Low Dose | Experimental | Valsartan Monotherapy 80 mg Receives: Drug: Valsartan 1 |
| Valsartan High Dose | Experimental | Valsartan Monotherapy 160 mg Receives: Drug: Valsartan 2 |
| Placebo | Placebo comparator | Dose Matched placebo Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Sitting Diastolic Blood Pressure (DBP)
Measured: from basline to Week 8
Secondary outcomes (1)
Change in Sitting Systolic Blood Pressure (SBP)
Measured: from baseline to Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jan 2012 (estimated)
- Study startJan 2012
- Primary completionMar 2013
- Study completionMay 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Stage 1 HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 4,161 participants (actual)
Sponsor and investigators
- Lead sponsor
- Forest Laboratories
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- David B Bharucha, MD, PhD, FACC, Study director, Forest Laboratories
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01508026
- Sponsor's protocol ID
- NAC-MD-01
- Status last verified
- Mar 2014
- First submitted
- 9 Jan 2012
- Last updated
- 25 Apr 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M; NAC-MD-01 Study Investigators. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014 May 31;383(9932):1889-98. doi: 10.1016/S0140-6736(14)60614-0.
PubMed 24881993
Study at a glance
From the registry record, last updated by the sponsor on 25 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension
- ClinicalTrials.gov ID
- NCT01508026
- Acronym / sponsor ID
- NAC-MD-01
- Conditions
- Stage 1 Hypertension, Stage 2 Hypertension
- Keywords
- Stage 1, Stage 2, Hypertension
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 4,161 participants (actual)
- Lead sponsor
- Forest LaboratoriesIndustry (pharma, biotech, devices)
- Study start
- Jan 2012
- Primary completion
- Mar 2013 (actual)
- Study completion
- May 2013 (actual)
- First posted
- 11 Jan 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Nebivolol and Valsartan Fixed Dose Combination 1 | Experimental | Drug: Nebivolol and Valsartan 1Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg |
| Nebivolol and Valsartan Fixed Dose Combination 2 | Experimental | Drug: Nebivolol and Valsartan 2Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg |
| Nebivolol and Valsartan Fixed Dose Combination 3 | Experimental | Drug: Nebivolol and Valsartan 3Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg |
| Nebivolol Low Dose | Experimental | Drug: Nebivolol 1Nebivolol Monotherapy 5 mg |
| Nebivolol High Dose | Experimental | Drug: Nebivolol 2Nebivolol Monotherapy 20 mg |
| Valsartan Low Dose | Experimental | Drug: Valsartan 1Valsartan Monotherapy 80 mg |
| Valsartan High Dose | Experimental | Drug: Valsartan 2Valsartan Monotherapy 160 mg |
| Placebo | Placebo comparator | Drug: PlaceboDose Matched placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Male or female outpatients of age 18 years or above
- Patients diagnosed with stage 1 or stage 2 essential hypertension
- Normal physical examination findings, electrocardiogram (ECG) results and chest x-ray; or abnormal findings judged by the Investigator to be not clinically significant
Key exclusion criteria (6 listed)
- Secondary hypertension or severe hypertension
- Clinically significant cardiovascular disease or heart failure
- Clinical significant respiratory disease that would prohibit the use of a beta blocker
- A medical contraindication to discontinuing a current antihypertensive therapy
- History of Type 1 diabetes mellitus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nebivolol and Valsartan 1Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration | Drug | Nebivolol and Valsartan Fixed Dose Combination 1 |
| Nebivolol and Valsartan 2Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration | Drug | Nebivolol and Valsartan Fixed Dose Combination 2 |
| Nebivolol and Valsartan 3Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration | Drug | Nebivolol and Valsartan Fixed Dose Combination 3 |
| Nebivolol 1Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration | Drug | Nebivolol Low Dose |
| Nebivolol 2Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration | Drug | Nebivolol High Dose |
| Valsartan 1Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration | Drug | Valsartan Low Dose |
| Valsartan 2Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration | Drug | Valsartan High Dose |
| PlaceboDose matched placebo, oral administration | Drug | Placebo |
Primary outcome
Change in Sitting Diastolic Blood Pressure (DBP)
Time frame: from basline to Week 8
1 secondary outcome
Change in Sitting Systolic Blood Pressure (SBP)
Time frame: from baseline to Week 8
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Apr 2014.
- Derived from this study: PubMed 24881993Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M; NAC-MD-01 Study Investigators. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014 May 31;383(9932):1889-98. doi: 10.1016/S0140-6736(14)60614-0.
Related trials for Stage 1 Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
Not yet recruitingPhase 1
Study of AB-110 in Healthy and Hypertensive Participants
Hypertension (HTN), Healthy Adult Participants
RecruitingPhase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Pulmonary Arterial Hypertension
Active, not recruitingPhase 1
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
Hypertension, Hypertension,Essential
Recruiting
Renal Denervation in Patients With Atrial Fibrillation and Hypertension
Atrial Fibrillation (Paroxysmal), Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David B Bharucha, MD, PhD, FACC study director
Forest Laboratories
413 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Nebivolol and Valsartan 1, Nebivolol and Valsartan 2 and Nebivolol and Valsartan 3 in people with Stage 1 Hypertension and Stage 2 Hypertension, run by Forest Laboratories at 413 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 413 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Sitting Diastolic Blood Pressure (DBP) (time frame: from basline to Week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01508026, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2014.